Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1967 1
1970 1
1971 1
1972 2
1973 1
1974 3
1975 1
1976 1
1977 2
1978 1
1979 1
1980 1
1981 2
1982 1
1983 5
1984 11
1985 5
1986 4
1987 13
1988 19
1989 16
1990 25
1991 39
1992 44
1993 51
1994 81
1995 82
1996 114
1997 137
1998 105
1999 136
2000 85
2001 110
2002 104
2003 97
2004 83
2005 83
2006 95
2007 162
2008 200
2009 180
2010 141
2011 172
2012 134
2013 134
2014 143
2015 159
2016 208
2017 182
2018 177
2019 80
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

3,319 results
Results by year
Filters applied: . Clear all
Page 1
Gadolinium Retention and Toxicity-An Update.
Ramalho M, et al. Adv Chronic Kidney Dis 2017 - Review. PMID 28501075
To date, no definitive clinical findings are associated with gadolinium deposition in brain tissue. Gadolinium deposition disease is a newly described and probably infrequent entity. ...In this review, we will address gadolinium toxicity focusing on these 2 recently described concerns....
To date, no definitive clinical findings are associated with gadolinium deposition in brain tissue. Gadolinium deposition dise …
Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates.
McDonald RJ, et al. Radiology 2018. PMID 30204075 Free PMC article.
Despite evidence that macrocyclic GBCAs show less gadolinium retention than linear GBCAs, the safety implications of gadolinium retention are unknown. The mechanism and chemical forms of gadolinium retention, as well as the biologic activity and clinical importance of these retained gadolinium species, remain poorly understood and underscore the need for additional research. ...
Despite evidence that macrocyclic GBCAs show less gadolinium retention than linear GBCAs, the safety implications of gadolinium
Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms.
Rogosnitzky M and Branch S. Biometals 2016 - Review. PMID 27053146 Free PMC article.
Gadolinium chelates are widely used as contrast media for magnetic resonance imaging. The approved gadolinium-based contrast agents (GBCAs) have historically been considered safe and well tolerated when used at recommended dosing levels. ...This review examines the potential biochemical and molecular basis of gadolinium toxicity, possible clinical significance of gadolinium tissue retention and accumulation, and methods that can limit gadolinium body burden....
Gadolinium chelates are widely used as contrast media for magnetic resonance imaging. The approved gadolinium-based contrast a
Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents.
Layne KA, et al. Br J Clin Pharmacol 2018 - Review. PMID 30032482 Free PMC article.
Every year, approximately 30 million magnetic resonance imaging scans are enhanced with gadolinium-based contrast agents (GBCAs) worldwide. ...We additionally evaluate the potential risk of toxicity from exposure to gadolinium in light of new guidance published by the US Food and Drug Administration and the European Medicines Agency, and discuss whether gadolinium deposition disease exists as a new diagnosis....
Every year, approximately 30 million magnetic resonance imaging scans are enhanced with gadolinium-based contrast agents (GBCAs) worl …
Gadolinium-Based Contrast Agent-Related Toxicities.
Pasquini L, et al. CNS Drugs 2018 - Review. PMID 29508245
In recent years, gadolinium-based contrast agents have been associated with different types of toxicity. In particular, nephrogenic systemic fibrosis, a progressive sclerotic-myxedematous systemic disease of unknown etiology, is related to gadolinium-based contrast agent administration in patients with kidney dysfunction. More recently, evidence of magnetic resonance signal intensity changes on pre-contrast T1-weighted images after multiple gadolinium-based contrast agent administrations resulted in the hypothesis of gadolinium brain accumulation in patients with normal renal function, subsequently confirmed in pathological samples. ...
In recent years, gadolinium-based contrast agents have been associated with different types of toxicity. In particular, nephrogenic s …
Safety of Contrast Material Use During Pregnancy and Lactation
Puac P, et al. Magn Reson Imaging Clin N Am 2017 - Review. PMID 28964468
This article addresses the different types of contrast media that may be used in such patients according to the imaging modality (iodinated contrast media, barium, gadolinium-based, and ultrasound contrast agents), focusing on their adverse effects, potential teratogenic effects, strategies to minimize risks, and current clinical recommendation....
This article addresses the different types of contrast media that may be used in such patients according to the imaging modality (iodinated …
Gadolinium-based contrast agents: A comprehensive risk assessment.
Fraum TJ, et al. J Magn Reson Imaging 2017 - Review. PMID 28083913
Gadolinium-based contrast agents (GBCAs) have been used in magnetic resonance imaging (MRI) since the 1980s and are now administered in up to 35% of all MRI examinations. ...Specific issues covered in this review article include immediate adverse reactions; pregnancy and lactation; and gadolinium deposition and toxicity, with a special focus on NSF. ...
Gadolinium-based contrast agents (GBCAs) have been used in magnetic resonance imaging (MRI) since the 1980s and are now administered
Immediate Allergic Reactions to Gadolinium-based Contrast Agents: A Systematic Review and Meta-Analysis.
Behzadi AH, et al. Radiology 2018 - Review. PMID 28846495
Purpose To perform a systematic review and meta-analysis to determine if there are differences in rates of immediate allergic events between classes of gadolinium-based contrast agents (GBCAs). ...
Purpose To perform a systematic review and meta-analysis to determine if there are differences in rates of immediate allergic events between …
The Evidence for and Against Corticosteroid Prophylaxis in At-Risk Patients
Davenport MS and Cohan RH. Radiol Clin North Am 2017 - Review. PMID 28126223
Corticosteroid prophylaxis is commonly used for the prevention of allergiclike reactions to iodinated and gadolinium-based contrast material in patients at highest risk of an allergiclike reaction. ...
Corticosteroid prophylaxis is commonly used for the prevention of allergiclike reactions to iodinated and gadolinium-based contrast m …
REPLY
Adin ME, et al. AJNR Am J Neuroradiol 2016. PMID 26494696 Free article.
3,319 results
Jump to page
Feedback